Drug Profile
CEVA 102
Alternative Names: Autologous or allogeneic mechano-transduced cells – Cellvation; CEVA102; Next-Gen MSCs – CellvationLatest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator University of Texas Health Science Center at Houston
- Developer Cellvation; University of Texas Health Science Center at Houston
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain injuries